Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can exercise protect diabetic joints? new study investigates

NCT ID NCT04893135

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how quickly bringing high blood sugar under control, combined with moderate treadmill walking, affects certain proteins linked to bone health in people with type 2 diabetes. The goal was to understand why some patients develop a rare but serious joint condition called Charcot neuroarthropathy. Sixty adults with poorly controlled diabetes participated, and researchers measured changes in the RANKL/OPG system, which regulates bone turnover.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
treadmill walking
What this could lead to
If successful, this could help explain why some diabetes patients develop joint problems, potentially pointing to ways to prevent it.
What could go wrong
This is a small, completed observational study with only 60 participants. It measures biological markers, not direct health outcomes, so results may not lead to clear treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Oct 2021

Finished

Oct 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Group G1: * Male or female patient aged 18 to 70, not practicing regular physical activity (Baecke score \<10) * Patient with type 2 diabetes for at least 1 year * Patient treated with metformin +/- SU +/- DPP4 inhibitor +/- GLP1 analogue +/- insulin therapy * Patient insufficiently balanced under his current treatment with an HbA1c level\> 8.5% for 6 months. * Patient able to practice physical activity on a regular basis * Patient having performed a coronary artery disease screening test in the year prior to inclusion * Woman of childbearing age with effective contraception put in place and monitored throughout the trial * Patient having given his consent to participate in the study and having signed an informed consent * Within the G1 group, a controlled 1: 1 randomization, stratified on age (≤65 years or\> 65 years) and BMI (≤ 30 or\> 30) will determine the inclusion of patients in the G1A group (correction of HbA1c) or G1B (correction of HbA1c + physical activity). Group G2: * Male or female patient aged 18 to 70, not practicing regular physical activity * Patient with type 2 diabetes for at least 1 year * Patient treated with metformin +/- SU +/- DPP4 inhibitor +/- GLP1 analogue +/- insulin therapy * Patient balanced under his current treatment with an HbA1c level \<7% for 6 months. * Women of childbearing potential with effective contraception put in place and monitored throughout the trial * Patient having given his consent to participate in the study and having signed an informed consent * Matching with the last patient included in group G1 on age (± 5 years), sex, duration of diabetes (± 2 years) and BMI (± 2kg / m2). Exclusion Criteria: * Fetal and maternal pathologies requiring maturation Patient with type 1 diabetes * Patient with regular physical activity * History of severe cardiovascular pathologies (myocardial infarction, or acute coronary syndrome, or stroke in the past year) * Patient with a history of severe hypoglycemia in the 6 months preceding entry into the study and / or not experiencing hypoglycemia at all * Patient pregnant or likely to be * Severe obesity (BMI\> 35kg / m2) * Other pathologies likely to interfere with the glycemic variation: in particular the use of corticosteroids during the study * Patient already having Charcot's neuroarthropathy or symptomatic autonomic neuropathy: orthostatic hypotension and / or gastro-paresis * Patient with preproliferative diabetic retinopathy * Patient having anti RANKL treatment * Subject under tutorship or curatorship * Subject not affiliated to social security.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes, France, 91100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.